{"id":"iproheptine","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["iproheptine","iproheptine hydrochloride","iproheptine HCl"],"offLabel":[],"synonyms":["iproheptine","iproheptine hydrochloride","iproheptine HCl"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and the key to unlocking these locks is a specific molecule. Iproheptine is a small molecule that fits into these locks, allowing it to influence the behavior of the cells and produce its therapeutic effects. This process is known as binding to a molecular target, and it's a key way that many drugs work.","oneSentence":"Iproheptine works by interacting with a specific molecular target to produce its therapeutic effects.","technicalDetail":"Iproheptine's mechanism of action is not well-characterized, but it is believed to involve binding to a specific receptor or enzyme, which triggers a cascade of downstream effects that ultimately produce its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3783","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IPROHEPTINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T13:59:56.293119","biosimilars":[],"competitors":[],"genericName":"iproheptine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"P021X7VTG0","CHEBI":"CHEBI:31720","INN_ID":"4090","UMLSCUI":"C2827214","ChEMBL_ID":"CHEMBL2103925","KEGG_DRUG":"D01515","PUBCHEM_CID":"19917","SECONDARY_CAS_RN":"4013-92-7"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"IPROHEPTINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iproheptine is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. The drug's pharmacokinetic properties, including half-life and bioavailability, are also unknown. Iproheptine's safety profile and potential side effects are not well-documented. Further research is needed to understand its mechanism of action and potential therapeutic applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}